Chardan Capital Has Lowered Expectations for uniQure (NASDAQ:QURE) Stock Price

uniQure (NASDAQ:QURE) had its target price decreased by equities research analysts at Chardan Capital from $76.00 to $53.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Chardan Capital’s price objective points to a potential upside of 54.56% from the stock’s previous close.

Several other brokerages also recently issued reports on QURE. Mizuho lifted their price objective on uniQure from $30.00 to $60.00 and gave the company an “outperform” rating in a research report on Thursday, September 25th. UBS Group set a $95.00 price objective on uniQure in a research report on Thursday, September 25th. Leerink Partners lifted their price objective on uniQure from $48.00 to $68.00 and gave the company an “outperform” rating in a research report on Wednesday, September 24th. Guggenheim lifted their price objective on uniQure from $28.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, September 25th. Finally, Royal Bank Of Canada reiterated an “outperform” rating on shares of uniQure in a research report on Wednesday, September 24th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, uniQure presently has a consensus rating of “Moderate Buy” and a consensus price target of $69.83.

uniQure Price Performance

QURE stock traded down $33.40 during trading on Monday, hitting $34.29. The company had a trading volume of 30,526,500 shares, compared to its average volume of 2,120,411. The company has a fifty day moving average price of $40.74 and a two-hundred day moving average price of $23.75. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53. The company has a market cap of $1.88 billion, a P/E ratio of -8.75 and a beta of 0.56. uniQure has a fifty-two week low of $5.35 and a fifty-two week high of $71.50.

Insiders Place Their Bets

In related news, CFO Christian Klemt sold 15,000 shares of uniQure stock in a transaction on Friday, September 26th. The stock was sold at an average price of $55.00, for a total transaction of $825,000.00. Following the completion of the sale, the chief financial officer directly owned 217,730 shares of the company’s stock, valued at $11,975,150. The trade was a 6.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Matthew C. Kapusta sold 226,316 shares of uniQure stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $41.46, for a total value of $9,383,061.36. Following the sale, the chief executive officer directly owned 651,454 shares of the company’s stock, valued at approximately $27,009,282.84. This trade represents a 25.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 244,316 shares of company stock valued at $10,328,181. 4.79% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Private Trust Co. NA acquired a new position in uniQure in the third quarter valued at about $28,000. Ballentine Partners LLC acquired a new position in shares of uniQure during the third quarter worth about $301,000. Tower Research Capital LLC TRC boosted its position in shares of uniQure by 358.0% during the second quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock worth $99,000 after buying an additional 5,538 shares during the period. Campbell & CO Investment Adviser LLC acquired a new position in shares of uniQure during the third quarter worth about $454,000. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of uniQure during the second quarter worth about $117,000. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.